Status:
COMPLETED
Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Photosensitive Epilepsy
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.
Eligibility Criteria
Inclusion
- diagnosis of photosensitive epilepsy
Exclusion
- \- inconsistent photoparoxysmal response when stimulated by photic stimulation
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00784212
Start Date
October 1 2008
End Date
September 1 2010
Last Update
September 23 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigator Site
Bielefeld, Germany
2
Novartis Investigator Site
Kehl-Kork, Germany
3
Novartis Investigator Site
Kiel, Germany
4
Novartis Investigator Site
Radeberg, Germany